157 related articles for article (PubMed ID: 37363962)
1. A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.
George S; Heinrich MC; Somaiah N; Oppelt P; McLeod R; Nishioka S; Kundu MG; Qian X; Kumar P; Laadem A; Lau Y; Tran BP; Fallon M; Dosunmu O; Shi J; Naito Y
Clin Cancer Res; 2023 Sep; 29(18):3659-3667. PubMed ID: 37363962
[TBL] [Abstract][Full Text] [Related]
2. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.
Iida K; Abdelhamid Ahmed AH; Nagatsuma AK; Shibutani T; Yasuda S; Kitamura M; Hattori C; Abe M; Hasegawa J; Iguchi T; Karibe T; Nakada T; Inaki K; Kamei R; Abe Y; Nomura T; Andersen JL; Santagata S; Hemming ML; George S; Doi T; Ochiai A; Demetri GD; Agatsuma T
Cancer Discov; 2021 Jun; 11(6):1508-1523. PubMed ID: 33579785
[TBL] [Abstract][Full Text] [Related]
3. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Heinrich MC; Jones RL; von Mehren M; Schöffski P; Serrano C; Kang YK; Cassier PA; Mir O; Eskens F; Tap WD; Rutkowski P; Chawla SP; Trent J; Tugnait M; Evans EK; Lauz T; Zhou T; Roche M; Wolf BB; Bauer S; George S
Lancet Oncol; 2020 Jul; 21(7):935-946. PubMed ID: 32615108
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.
Li J; Zhang X; Deng Y; Wu X; Zheng Z; Zhou Y; Cai S; Zhang Y; Zhang J; Tao K; Cui Y; Cao H; Shen K; Yu J; Zhou Y; Ren W; Qu C; Zhao W; Hu J; Wang W; Yang J; Shen L
Oncologist; 2023 Feb; 28(2):187-e114. PubMed ID: 36477870
[TBL] [Abstract][Full Text] [Related]
5. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
Rosenbaum E; Kelly C; D'Angelo SP; Dickson MA; Gounder M; Keohan ML; Movva S; Condy M; Adamson T; Mcfadyen CR; Antonescu CR; Hwang S; Singer S; Qin LX; Tap WD; Chi P
Oncologist; 2019 Oct; 24(10):1309-e983. PubMed ID: 31213500
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
11. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Kim R; Leal AD; Parikh A; Ryan DP; Wang S; Bahamon B; Gupta N; Moss A; Pye J; Miao H; Inguilizian H; Cleary JM
Cancer Chemother Pharmacol; 2023 Apr; 91(4):291-300. PubMed ID: 36738333
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
13. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
15. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
King GT; Eaton KD; Beagle BR; Zopf CJ; Wong GY; Krupka HI; Hua SY; Messersmith WA; El-Khoueiry AB
Invest New Drugs; 2018 Oct; 36(5):836-847. PubMed ID: 29333575
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.
Verschuur AC; Bajčiová V; Mascarenhas L; Khosravan R; Lin X; Ingrosso A; Janeway KA
Cancer Chemother Pharmacol; 2019 Jul; 84(1):41-50. PubMed ID: 31006038
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
Kelly CM; Shoushtari AN; Qin LX; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Mcfadyen C; Sjoberg A; Singer S; DeMatteo RP; Hwang S; Heinemann MH; Francis JH; Antonescu CR; Chi P; Tap WD
Invest New Drugs; 2019 Apr; 37(2):282-290. PubMed ID: 30101387
[TBL] [Abstract][Full Text] [Related]
18. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna K; Kalebic T; Cruz C; Faris JE; Ryan DP; Jung J; Wyant T; Fasanmade AA; Messersmith W; Rodon J
Clin Cancer Res; 2016 Oct; 22(20):5049-5057. PubMed ID: 27178743
[TBL] [Abstract][Full Text] [Related]
20. HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial.
Zhu X; Ding Y; Wang Q; Yang G; Zhou L; Wang Q
Invest New Drugs; 2023 Jun; 41(3):473-482. PubMed ID: 37140695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]